代谢综合征与帕金森病发病风险:社区纵向研究及荟萃分析
基于英国生物银行467,200名无帕金森病成人的前瞻性队列显示,代谢综合征与帕金森病发病风险升高相关(HR 1.39),代谢综合征组分数量呈剂量依赖关联,高遗传风险者风险最高(HR 2.58)。荟萃分析合并24,789,538名参与者,汇总相对风险为1.29。
要点
- 代谢综合征与帕金森病发病风险升高相关,HR为1.39(95%CI 1.11-1.74)。
- 代谢综合征组分数量越多,帕金森病风险越高(HR 1.14,趋势P=0.001)。
- 代谢综合征合并高多基因风险评分者帕金森病风险最高(HR 2.58)。
核心结论
- 代谢综合征与帕金森病发病风险升高相关,尤其在高遗传易感人群中更显著。
研究设计与样本
- 前瞻性队列研究纳入英国生物银行37-73岁无帕金森病成人467,200名,平均年龄56.53±8.09岁,女性占54.26%。
- 代谢综合征定义为以下5项中≥3项:腰围升高、高血压、血脂异常、高甘油三酯血症、高血糖。
- 帕金森病诊断基于医疗记录,并计算基于26个帕金森病相关等位基因的多基因风险评分。
- 采用Cox回归分析,并整合8项其他观察性研究进行荟萃分析。
主要发现
- 随访期间(6,605.9×1,000人年)共3,222人发生帕金森病,发病率为5.01/10,000人年(95%CI 4.84-5.18)。
- 代谢综合征患者帕金森病风险比为1.39(95%CI 1.11-1.74)。
- 代谢综合征组分数量与帕金森病风险呈剂量依赖关联(HR 1.14,95%CI 1.05-1.24;趋势P=0.001)。
- 代谢综合征且高多基因风险评分者帕金森病风险最高(HR 2.58,95%CI 2.12-3.14;交互作用P=0.002)。
- 荟萃分析纳入24,789,538名参与者、98,582例新发帕金森病,汇总相对风险为1.29(95%CI 1.15-1.44)。
临床怎么用
- 在临床评估中,可将代谢综合征及其组分数量作为帕金森病风险筛查的参考因素。
- 对于代谢综合征合并高遗传风险的患者,应加强帕金森病相关症状的监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The association between metabolic syndrome (MetS) and incident Parkinson disease (PD) remains equivocal. We aimed to investigate the association of MetS and its components with the risk of PD and to explore the role of genetic background in the MetS-PD association. METHODS: This prospective cohort study included PD-free adults aged 37-73 years from the UK Biobank. MetS was defined as presence of 3 or more of the following: elevated waist circumference (≥102 cm for men; ≥88 cm for women), hypertension (systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or use of antihypertensive medication), dyslipidemia (high-density lipoprotein cholesterol <1.04 mmol/L for men or <1.30 mmol/L for women or use of lipid-lowering medication), hypertriglyceridemia (triglycerides ≥1.70 mmol/L or use of lipid-lowering medication), and hyperglycemia (HbA1c ≥ 5.7%). PD was diagnosed based on information from medical records. PD-related polygenic risk score (PRSPD) was calculated based on the presence of 26 PD-related alleles and categorized as low, moderate, or high. Data were analyzed using Cox regression. In addition, a meta-analysis was conducted by integrating the present UK Biobank data with findings from 8 other observational studies. RESULTS: The study included 467,200 participants (mean age 56.53 ± 8.09 years; 54.26% female), 177,407 (37.97%) of whom had MetS. Over the follow-up (6,605.9 × 1,000 person-years), 3,222 participants developed PD (5.01 [95% CI 4.84-5.18] per 10,000 person-years, age-specified and sex-specified). The hazard ratio of PD was 1.39 (1.11-1.74) for participants with MetS compared with those who were MetS-free. Furthermore, having a higher number of MetS components was dose-dependently associated with higher PD risk (HR: 1.14 [1.05-1.24]; p for trend = 0.001). In addition, PD risk was highest among participants with MetS and high PRSPD (HR: 2.58 [2.12-3.14]; p for interaction = 0.002). In a meta-analysis of 24,789,538 participants with 98,582 incident cases of PD, the pooled relative risk of PD was 1.29 (1.15-1.44) for participants with MetS. DISCUSSION: Supported by evidence from meta-analysis, MetS was associated with higher risk of incident PD, especially in people with a high genetic predisposition for PD.
引用
- Zhang X, Wang J, Dove A, et al. Metabolic Syndrome and Incidence of Parkinson Disease: A Community-Based Longitudinal Study and Meta-Analysis. Neurology. 2025. PMID: 40834329. doi:10.1212/WNL.0000000000214033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。